IP Library Patent Application 16984515
Patent Application
App. No. 16/984,515

Method of Treating or Preventing Rheumatoid Arthritis

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/984,515
Abstract

This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline-related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.

Claims (11)

1 .- 4 . (canceled)

5 . A method for treating Rheumatoid arthritis, comprising the step of administering to a patient in need thereof a therapeutically effective amount of an antibody that specifically reacts with a citrullinated epitope present on a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO 24 and SEQ ID NO: 26.

6 .- 9 . (canceled)

10 . The method according to claim 5 , wherein the antibody comprises:

a heavy chain CDR1 domain comprising the polypeptide encoded by positions 76-99 of SEQ ID NO: 44;

a heavy chain CDR2 domain comprising the polypeptide encoded by positions 151-174 of SEQ ID NO: 44;

a heavy chain CDR3 domain comprising the polypeptide encoded by positions 289-333 of SEQ ID NO: 44;

a light chain CDR1 domain comprising the polypeptide encoded by positions 79-111 of SEQ ID NO: 45;

a light chain CDR2 domain comprising the polypeptide encoded by positions 163-171 of SEQ ID NO: 45; and

a light chain CDR3 domain comprising the polypeptide encoded by positions 280-306 of SEQ ID NO: 45

11 . An antibody that specifically reacts with a citrullinated epitope present on a peptide comprising the amino acid sequence of SEQ ID NO: 21.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 055893 FRAME: 0281. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER . Recorded Apr 14, 2021
From: CITRYLL IP B.V.
To: CITRYLL B.V.
Reel/Frame 055942/0235 →
MERGER Recorded Apr 12, 2021
From: CITRYLL IP B.V.
To: CITRYLL IP B.V.
Reel/Frame 055893/0281 →
DE-MERGER Recorded Apr 12, 2021
From: MODIQUEST B.V.
To: CITRYLL IP BV
Reel/Frame 055901/0828 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2020
From: RAATS, JOZEF MARIA HENDRIK; CHIRIVI, RENATO GERARDUS SILVANO
To: MODIQUEST B.V.
Reel/Frame 053394/0852 →